Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
France
Institut Bergonié, Bordeaux Italy
Istituto Clinico Humanitas, Rozzano, Milan Centro di Referimento Ocologico, Aviano Istituto Ortopedico Rizzoli, Bologna